drugset / Trial / NCT03706703
Rh-Endostatin (Endostar®) Continuous Intravenous Infusion
NaSingle-groupOpen-labelTreatment
Summary
Endostar is a anti-angiogenesis product and has been launched in China . The efficacy and safety have been defined. However, the compliance is unsatisfactory since routine i.v of Endostar is needed for 3 to 4 hours daily during one cycle of 14 days. The continuous intravenous infusion by using venous pump can improve the compliance.
Timeline
- Start
- 2018-10-01
- Primary completion
- 2020-04-01
- Completion
- 2020-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Endostar | Protein / enzyme biologic | 7.5 mg/m2 | Intravenous |
| Background | Carboplatin | Small molecule | — | — |
| Background | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Background | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |